ProCite
RefWorks
Reference Manager
BibTeX
Zotero
EndNote
-
1.
Roth GA et al., 2018. Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet 392: 1736–1788.
-
2.
WHO , 2017. Global Hepatitis Report, 2017. Available at: http://www.who.int/hepatitis/publications/global-hepatitis-report2017/en/. Accessed January 17, 2023.
-
3.
World Health Organization WHO Hepatitis B Fact Sheet. Available at: http://www.who.int/mediacentre/factsheets/fs204/en/. Accessed January 2, 2023.
-
4.
Belyhun Y, Maier M, Mulu A, Diro E, Liebert UG, 2016. Hepatitis viruses in Ethiopia: a systematic review and meta-analysis. BMC Infect Dis 16: 761.
-
5.
Anugwom CM, Allaire M, Akbar SM, Sultan A, Bollipo S, Mattos AZ, Debes JD, 2021. Hepatitis B–related hepatocellular carcinoma: surveillance strategy directed by immune-epidemiology. Hepatoma Res 7: 23.
-
6.
Kuper H, Tzonou A, Kaklamani E, Hsieh CC, Lagiou P, Adami HO, Trichopoulos D, Stuver SO, 2000. Tobacco smoking, alcohol consumption and their interaction in the causation of hepatocellular carcinoma. Int J Cancer 85: 498–502.
-
7.
Orlien SMS, Berhe NB, Morgan MY, Johannessen A, 2019. Khat-related liver disease in sub-Saharan Africa: neglected, yet important. Lancet Glob Health 7: e310.
-
8.
Leathers JS, Pisano MB, Re V, Van Oord G, Sultan A, Boonstra A, Debes JD, 2019. Evaluation of Rapid Diagnostic Tests for Assessment of Hepatitis B in Resource-Limited Settings. Ann Glob Health 85: 98.
-
9.
Marcellin P et al., 2013. Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study. Lancet 381: 468–475.
-
10.
Kim WR et al., 2015. Impact of long-term tenofovir disoproxil fumarate on incidence of hepatocellular carcinoma in patients with chronic hepatitis B. Cancer 121: 3631–3638.
-
11.
Yang JD et al., 2017. Characteristics, management, and outcomes of patients with hepatocellular carcinoma in Africa: a multicountry observational study from the Africa Liver Cancer Consortium. Lancet Gastroenterol Hepatol 2: 103–111.
-
12.
Wong DKH et al., 2020. Among patients with undetectable hepatitis B surface antigen and hepatocellular carcinoma, a high proportion has integration of HBV DNA into hepatocyte DNA and no cirrhosis. Clin Gastroenterol Hepatol 18: 449–456.
-
13.
Zampino R, Boemio A, Sagnelli C, Alessio L, Adinolfi LE, Sagnelli E, Coppola N, 2015. Hepatitis B virus burden in developing countries. World J Gastroenterol 21: 11941–11953.
-
14.
Aberra H, Desalegn H, Berhe N, Medhin G, Stene-Johansen K, Gundersen SG, Johannessen A, 2017. Early experiences from one of the first treatment programs for chronic hepatitis B in sub-Saharan Africa. BMC Infect Dis 17: 1–9.
-
15.
Desalegn H, Aberra H, Berhe N, Mekasha B, Stene-Johansen K, Krarup H, Pereira AP, Gundersen SG, Johannessen A, 2018. Treatment of chronic hepatitis B in sub-Saharan Africa: 1-year results of a pilot program in Ethiopia. BMC Med 16: 1–10.
-
16.
Johannessen A, Tadesse Gebremedhin L, Desalegn H, 2022. Comment new WHO hepatitis B treatment guidelines: look to Ethiopia. Lancet Glob Health 10: e1711–e1712.
-
17.
Setiawan VW, Wilkens LR, Lu SC, Hernandez BY, Le Marchand L, Henderson BE, 2015. Association of coffee intake with reduced incidence of liver cancer and death from chronic liver disease in the US multiethnic cohort. Gastroenterology 148: 118–125.
-
18.
Kennedy OJ, Roderick P, Buchanan R, Fallowfield JA, Hayes PC, Parkes J, 2016. Systematic review with meta-analysis: coffee consumption and the risk of cirrhosis. Aliment Pharmacol Ther 43: 562–574.
-
19.
Heath RD, Brahmbhatt M, Tahan AC, Ibdah JA, Tahan V, 2017. Coffee: the magical bean for liver diseases. World J Hepatol 9: 689–696.
-
20.
Gressner OA, Lahme B, Rehbein K, Siluschek M, Weiskirchen R, Gressner AM, 2008. Pharmacological application of caffeine inhibits TGF-β-stimulated connective tissue growth factor expression in hepatocytes via PPARγ and SMAD2/3-dependent pathways. J Hepatol 49: 758–767.
| Past two years | Past Year | Past 30 Days | |
|---|---|---|---|
| Abstract Views | 2440 | 685 | 33 |
| Full Text Views | 188 | 63 | 16 |
| PDF Downloads | 91 | 40 | 0 |
Clinical, Gender, Socioeconomic Characteristics and Outcomes of Individuals Receiving Hepatitis B Treatment in Ethiopia: 18-Month Follow-Up
Manaswita Tappata
Manaswita Tappata
Department of Medicine, University of Minnesota, Minneapolis, Minnesota;
Search for other papers by Manaswita Tappata in
Current site
Google Scholar
PubMed
Search for other papers by Manaswita Tappata in
Current site
Google Scholar
PubMed
Marina Farah
Marina Farah
Department of Medical Education, University of Balamand, Beirut, Lebanon;
Search for other papers by Marina Farah in
Current site
Google Scholar
PubMed
Search for other papers by Marina Farah in
Current site
Google Scholar
PubMed
Chimaobi Anugwom
Chimaobi Anugwom
Department of Medicine, University of Minnesota, Minneapolis, Minnesota;
HealthPartners Digestive Care, St. Paul, Minnesota;
Search for other papers by Chimaobi Anugwom in
Current site
Google Scholar
PubMed
HealthPartners Digestive Care, St. Paul, Minnesota;
Search for other papers by Chimaobi Anugwom in
Current site
Google Scholar
PubMed
Eden Bisrat
Eden Bisrat
Department of Internal Medicine, Addis Ababa University, Addis Ababa, Ethiopia;
Search for other papers by Eden Bisrat in
Current site
Google Scholar
PubMed
Search for other papers by Eden Bisrat in
Current site
Google Scholar
PubMed
Amir S. Seid
Amir S. Seid
Department of Medicine, University of Minnesota, Minneapolis, Minnesota;
Department of Internal Medicine, Addis Ababa University, Addis Ababa, Ethiopia;
Search for other papers by Amir S. Seid in
Current site
Google Scholar
PubMed
Department of Internal Medicine, Addis Ababa University, Addis Ababa, Ethiopia;
Search for other papers by Amir S. Seid in
Current site
Google Scholar
PubMed
Jose D. Debes
Jose D. Debes
Department of Medicine, University of Minnesota, Minneapolis, Minnesota;
Department of Gastroenterology, Erasmus MC, Rotterdam, The Netherlands
Search for other papers by Jose D. Debes in
Current site
Google Scholar
PubMed
Department of Gastroenterology, Erasmus MC, Rotterdam, The Netherlands
Search for other papers by Jose D. Debes in
Current site
Google Scholar
PubMed
ABSTRACT.
There is a lack of real-world data on hepatitis B (HBV) treatment in Africa. We conducted a single-center 18-month prospective cohort study in Ethiopia to understand clinical, laboratory, and demographic variables associated with HBV treatment. One hundred fifty HBV-positive patients were included: 51 on treatment, 99 with no treatment. Median age was similar between groups. Those on treatment were more likely to be male (86%), report higher coffee intake (90% versus 70%, P < 0.05), lower khat intake (0% versus 9%, P = 0.08), lower alcohol consumption (0% versus 5%, P = 0.1), and had attained higher levels of education (56% versus 42%, P = 0.19). Individuals on treatment had higher median aspartate aminotransferase (AST), alanine aminotransferase (ALT), HBV DNA, and median Aminotransferase-to-Platelet Ratio Index and Fibrosis-4 scores. At 6 and 12 months, those on treatment showed a decrease in median AST, ALT, and fibrosis scores and had less hepatocellular carcinoma development at 6 months (2% versus 4%). Our study highlights potential demographic disparities in HBV treatment as well as benefits in a real-life setting in Africa.
Author Notes
Financial support: Academic Investment Research Program (AIRP) University of Minnesota and National Institutes of Health (NIH) grant 1R21TW012390-01A1, both to J. D. D.
Authors’ addresses: Manaswita Tappata, Department of Medicine, University of Minnesota, Minneapolis, MN, E-mail: tappa029@umn.edu. Marina Farah, Department of Medical Education, University of Balamand, Beirut, Lebanon, E-mail: mwf06@mail.aub.edu. Chimaobi Anugwom, Department of Medicine, University of Minnesota, Minneapolis, MN, and Health Partners Digestive Care, St. Paul, Minnesota, E-mail: anugw001@umn.edu. Eden Bisrat, Department of Internal Medicine, Addis Ababa University, Addis Ababa, Ethiopia, E-mail: edenbisrat13@gmail.com. Amir S. Seid, Department of Medicine, University of Minnesota, Minneapolis, MN, and Department of Internal Medicine, Addis Ababa University, Addis Ababa, Ethiopia, E-mail: seid0131@umn.edu. Jose D. Debes, Department of Medicine, University of Minnesota, Minneapolis, MN, and Department of Gastroenterology, Erasmus MC, Rotterdam, The Netherlands, E-mail: debes003@umn.edu
ProCite
RefWorks
Reference Manager
BibTeX
Zotero
EndNote
-
1.
Roth GA et al., 2018. Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet 392: 1736–1788.
-
2.
WHO , 2017. Global Hepatitis Report, 2017. Available at: http://www.who.int/hepatitis/publications/global-hepatitis-report2017/en/. Accessed January 17, 2023.
-
3.
World Health Organization WHO Hepatitis B Fact Sheet. Available at: http://www.who.int/mediacentre/factsheets/fs204/en/. Accessed January 2, 2023.
-
4.
Belyhun Y, Maier M, Mulu A, Diro E, Liebert UG, 2016. Hepatitis viruses in Ethiopia: a systematic review and meta-analysis. BMC Infect Dis 16: 761.
-
5.
Anugwom CM, Allaire M, Akbar SM, Sultan A, Bollipo S, Mattos AZ, Debes JD, 2021. Hepatitis B–related hepatocellular carcinoma: surveillance strategy directed by immune-epidemiology. Hepatoma Res 7: 23.
-
6.
Kuper H, Tzonou A, Kaklamani E, Hsieh CC, Lagiou P, Adami HO, Trichopoulos D, Stuver SO, 2000. Tobacco smoking, alcohol consumption and their interaction in the causation of hepatocellular carcinoma. Int J Cancer 85: 498–502.
-
7.
Orlien SMS, Berhe NB, Morgan MY, Johannessen A, 2019. Khat-related liver disease in sub-Saharan Africa: neglected, yet important. Lancet Glob Health 7: e310.
-
8.
Leathers JS, Pisano MB, Re V, Van Oord G, Sultan A, Boonstra A, Debes JD, 2019. Evaluation of Rapid Diagnostic Tests for Assessment of Hepatitis B in Resource-Limited Settings. Ann Glob Health 85: 98.
-
9.
Marcellin P et al., 2013. Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study. Lancet 381: 468–475.
-
10.
Kim WR et al., 2015. Impact of long-term tenofovir disoproxil fumarate on incidence of hepatocellular carcinoma in patients with chronic hepatitis B. Cancer 121: 3631–3638.
-
11.
Yang JD et al., 2017. Characteristics, management, and outcomes of patients with hepatocellular carcinoma in Africa: a multicountry observational study from the Africa Liver Cancer Consortium. Lancet Gastroenterol Hepatol 2: 103–111.
-
12.
Wong DKH et al., 2020. Among patients with undetectable hepatitis B surface antigen and hepatocellular carcinoma, a high proportion has integration of HBV DNA into hepatocyte DNA and no cirrhosis. Clin Gastroenterol Hepatol 18: 449–456.
-
13.
Zampino R, Boemio A, Sagnelli C, Alessio L, Adinolfi LE, Sagnelli E, Coppola N, 2015. Hepatitis B virus burden in developing countries. World J Gastroenterol 21: 11941–11953.
-
14.
Aberra H, Desalegn H, Berhe N, Medhin G, Stene-Johansen K, Gundersen SG, Johannessen A, 2017. Early experiences from one of the first treatment programs for chronic hepatitis B in sub-Saharan Africa. BMC Infect Dis 17: 1–9.
-
15.
Desalegn H, Aberra H, Berhe N, Mekasha B, Stene-Johansen K, Krarup H, Pereira AP, Gundersen SG, Johannessen A, 2018. Treatment of chronic hepatitis B in sub-Saharan Africa: 1-year results of a pilot program in Ethiopia. BMC Med 16: 1–10.
-
16.
Johannessen A, Tadesse Gebremedhin L, Desalegn H, 2022. Comment new WHO hepatitis B treatment guidelines: look to Ethiopia. Lancet Glob Health 10: e1711–e1712.
-
17.
Setiawan VW, Wilkens LR, Lu SC, Hernandez BY, Le Marchand L, Henderson BE, 2015. Association of coffee intake with reduced incidence of liver cancer and death from chronic liver disease in the US multiethnic cohort. Gastroenterology 148: 118–125.
-
18.
Kennedy OJ, Roderick P, Buchanan R, Fallowfield JA, Hayes PC, Parkes J, 2016. Systematic review with meta-analysis: coffee consumption and the risk of cirrhosis. Aliment Pharmacol Ther 43: 562–574.
-
19.
Heath RD, Brahmbhatt M, Tahan AC, Ibdah JA, Tahan V, 2017. Coffee: the magical bean for liver diseases. World J Hepatol 9: 689–696.
-
20.
Gressner OA, Lahme B, Rehbein K, Siluschek M, Weiskirchen R, Gressner AM, 2008. Pharmacological application of caffeine inhibits TGF-β-stimulated connective tissue growth factor expression in hepatocytes via PPARγ and SMAD2/3-dependent pathways. J Hepatol 49: 758–767.
| Past two years | Past Year | Past 30 Days | |
|---|---|---|---|
| Abstract Views | 2440 | 685 | 33 |
| Full Text Views | 188 | 63 | 16 |
| PDF Downloads | 91 | 40 | 0 |